PIK3CD and neoplasm: Interestingly, MEK inhibition by AZD6244 alone remained cytostatic until it was combined with the PI3K-inhibitor BKM120 or erlotinib, which delayed tumor formation and improved overall survival compared with single-agent therapy (Alagesan et al., 2015; NCT01222689).